Nikola Pantic, Lenka Grujicic, Branislava Radovic, Dragana Sobic Saranovic, Vera Artiko, Strahinja Odalovic
{"title":"18f -氟胆碱和18f -氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描在甲状旁腺癌患者评价中的互补作用:1例报告。","authors":"Nikola Pantic, Lenka Grujicic, Branislava Radovic, Dragana Sobic Saranovic, Vera Artiko, Strahinja Odalovic","doi":"10.4274/mirt.galenos.2025.58966","DOIUrl":null,"url":null,"abstract":"<p><p><sup>18</sup>Fluorine-fluorocholine (<sup>18</sup>F-FCH) is a radiopharmaceutical used in primary hyperparathyroidism. The data about its utility in malignancies other than prostate and hepatocellular carcinoma is limited. We present the case of a patient who was referred for <sup>18</sup>F-FCH positron emission tomography/computed tomography (PET/CT) due to the persistently elevated parathormone and calcium levels following total thyroidectomy with left lower parathyroidectomy for parathyroid carcinoma (PTC). Previously, the patient underwent <sup>18</sup>Fluorine-fluorodeoxyglucose (<sup>18</sup>F-FDG) PET/CT. The latter method detected multiple mediastinal and hilar lymph nodes, as well as nodular lesions in lungs and osteolytic bone lesions with an increased tracer uptake, whereas <sup>18</sup>F-FCH PET/CT detected an increased tracer uptake not only in lesions at all of the abovementioned areas, but also in the nodular lesion in the neck corresponding to a local relapse as well, with bone lesions showing higher avidity for <sup>18</sup>F-FDG than for <sup>18</sup>F-FCH. The case we present shows that <sup>18</sup>F-FCH PET/CT has an additive value to <sup>18</sup>F-FDG PET/CT in an evaluation of patients with PTC.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Complementary Roles of <sup>18</sup>F-Fluorocholine and <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in an Evaluation of A Patient With Parathyroid Carcinoma: A Case Report.\",\"authors\":\"Nikola Pantic, Lenka Grujicic, Branislava Radovic, Dragana Sobic Saranovic, Vera Artiko, Strahinja Odalovic\",\"doi\":\"10.4274/mirt.galenos.2025.58966\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><sup>18</sup>Fluorine-fluorocholine (<sup>18</sup>F-FCH) is a radiopharmaceutical used in primary hyperparathyroidism. The data about its utility in malignancies other than prostate and hepatocellular carcinoma is limited. We present the case of a patient who was referred for <sup>18</sup>F-FCH positron emission tomography/computed tomography (PET/CT) due to the persistently elevated parathormone and calcium levels following total thyroidectomy with left lower parathyroidectomy for parathyroid carcinoma (PTC). Previously, the patient underwent <sup>18</sup>Fluorine-fluorodeoxyglucose (<sup>18</sup>F-FDG) PET/CT. The latter method detected multiple mediastinal and hilar lymph nodes, as well as nodular lesions in lungs and osteolytic bone lesions with an increased tracer uptake, whereas <sup>18</sup>F-FCH PET/CT detected an increased tracer uptake not only in lesions at all of the abovementioned areas, but also in the nodular lesion in the neck corresponding to a local relapse as well, with bone lesions showing higher avidity for <sup>18</sup>F-FDG than for <sup>18</sup>F-FCH. The case we present shows that <sup>18</sup>F-FCH PET/CT has an additive value to <sup>18</sup>F-FDG PET/CT in an evaluation of patients with PTC.</p>\",\"PeriodicalId\":44681,\"journal\":{\"name\":\"Molecular Imaging and Radionuclide Therapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Imaging and Radionuclide Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4274/mirt.galenos.2025.58966\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Radionuclide Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/mirt.galenos.2025.58966","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
The Complementary Roles of 18F-Fluorocholine and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in an Evaluation of A Patient With Parathyroid Carcinoma: A Case Report.
18Fluorine-fluorocholine (18F-FCH) is a radiopharmaceutical used in primary hyperparathyroidism. The data about its utility in malignancies other than prostate and hepatocellular carcinoma is limited. We present the case of a patient who was referred for 18F-FCH positron emission tomography/computed tomography (PET/CT) due to the persistently elevated parathormone and calcium levels following total thyroidectomy with left lower parathyroidectomy for parathyroid carcinoma (PTC). Previously, the patient underwent 18Fluorine-fluorodeoxyglucose (18F-FDG) PET/CT. The latter method detected multiple mediastinal and hilar lymph nodes, as well as nodular lesions in lungs and osteolytic bone lesions with an increased tracer uptake, whereas 18F-FCH PET/CT detected an increased tracer uptake not only in lesions at all of the abovementioned areas, but also in the nodular lesion in the neck corresponding to a local relapse as well, with bone lesions showing higher avidity for 18F-FDG than for 18F-FCH. The case we present shows that 18F-FCH PET/CT has an additive value to 18F-FDG PET/CT in an evaluation of patients with PTC.
期刊介绍:
Molecular Imaging and Radionuclide Therapy (Mol Imaging Radionucl Ther, MIRT) is publishes original research articles, invited reviews, editorials, short communications, letters, consensus statements, guidelines and case reports with a literature review on the topic, in the field of molecular imaging, multimodality imaging, nuclear medicine, radionuclide therapy, radiopharmacy, medical physics, dosimetry and radiobiology.